[go: up one dir, main page]

UY30629A1 - Nuevo péptido de actinomadura namibiensis - Google Patents

Nuevo péptido de actinomadura namibiensis

Info

Publication number
UY30629A1
UY30629A1 UY30629A UY30629A UY30629A1 UY 30629 A1 UY30629 A1 UY 30629A1 UY 30629 A UY30629 A UY 30629A UY 30629 A UY30629 A UY 30629A UY 30629 A1 UY30629 A1 UY 30629A1
Authority
UY
Uruguay
Prior art keywords
new peptide
actinomadura namibiensis
namibiensis
actinomadura
infections
Prior art date
Application number
UY30629A
Other languages
English (en)
Inventor
Dr Kathrin Meindl
Prof Dr George Sheldrick
Prof Dr Roderich Soessmuth
Dr Irvin Winkler
Dr Jachim Wink
Dr Laszlo Vertesy
Prof Dr Gerhard Seibert
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37836831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY30629(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY30629A1 publication Critical patent/UY30629A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invencion se refiere a un compuesto de la formula (I) en la que m y n son, independientemente entre sí, 0, 1 o 2, que puede obtenerse a partir de Actinomadura namibiensis (DSM 6313), a su uso para el tratamiento de infecciones bacterianas, infecciones virales y/o dolor y a una composicion farmacéutica que lo comprende.
UY30629A 2006-10-06 2007-10-04 Nuevo péptido de actinomadura namibiensis UY30629A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06020980A EP1908774A1 (en) 2006-10-06 2006-10-06 Antibacterial and antiviral peptides from Actinomadura namibiensis

Publications (1)

Publication Number Publication Date
UY30629A1 true UY30629A1 (es) 2008-05-31

Family

ID=37836831

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30629A UY30629A1 (es) 2006-10-06 2007-10-04 Nuevo péptido de actinomadura namibiensis

Country Status (21)

Country Link
US (1) US8476222B2 (es)
EP (2) EP1908774A1 (es)
JP (1) JP5204779B2 (es)
KR (1) KR101504492B1 (es)
CN (1) CN101522705B (es)
AR (1) AR063140A1 (es)
AT (1) ATE525389T1 (es)
AU (1) AU2007304536B2 (es)
BR (1) BRPI0719978A2 (es)
CA (1) CA2665269C (es)
CL (1) CL2007002889A1 (es)
IL (1) IL197971A (es)
MA (1) MA31133B1 (es)
MX (1) MX2009002962A (es)
MY (1) MY147920A (es)
NO (1) NO20091788L (es)
NZ (1) NZ576039A (es)
RU (1) RU2451028C2 (es)
UY (1) UY30629A1 (es)
WO (1) WO2008040469A1 (es)
ZA (1) ZA200901321B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010010115A (es) * 2008-04-02 2010-09-30 Sanofi Aventis Peptidos muy puenteados a partir de actinomadura namibiensis.
EP2607374A1 (en) 2011-12-21 2013-06-26 Sanofi Method for recombinant production of labyrinthopeptins and functional derivatives thereof
CN103421100B (zh) * 2012-05-22 2015-11-18 中国科学院动物研究所 一种抗菌肽及其制备方法和应用
EP2872527B1 (en) 2012-07-12 2016-11-30 Naicons Srl Novel lantipeptide
US20190046604A1 (en) 2015-11-18 2019-02-14 Helmholtz-Zentrum für Infektionsforschung GmbH Labyrinthopeptins as anti-viral agents
CN106188253B (zh) * 2016-08-26 2020-08-18 上海交通大学 抗菌肽Lexapeptide及其制备方法和用途
CN110400607B (zh) * 2019-07-17 2020-06-02 杭州费尔斯通科技有限公司 一种分子式库的扩展方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19745583A1 (de) * 1997-10-15 1999-04-22 Hoechst Marion Roussel De Gmbh Neues Lantibiotikum verwandt mit Actagardine, Verfahren zur Herstellung und Verwendung derselben
MX2010010115A (es) * 2008-04-02 2010-09-30 Sanofi Aventis Peptidos muy puenteados a partir de actinomadura namibiensis.

Also Published As

Publication number Publication date
IL197971A0 (en) 2011-08-01
ATE525389T1 (de) 2011-10-15
ZA200901321B (en) 2009-12-30
AU2007304536A1 (en) 2008-04-10
RU2451028C2 (ru) 2012-05-20
BRPI0719978A2 (pt) 2014-08-12
MY147920A (en) 2013-02-15
KR101504492B1 (ko) 2015-03-23
CN101522705B (zh) 2013-10-02
WO2008040469A1 (en) 2008-04-10
CA2665269C (en) 2015-07-14
IL197971A (en) 2015-08-31
US20090298904A1 (en) 2009-12-03
JP2010505777A (ja) 2010-02-25
US8476222B2 (en) 2013-07-02
EP2076529B1 (en) 2011-09-21
EP1908774A1 (en) 2008-04-09
CN101522705A (zh) 2009-09-02
EP2076529A1 (en) 2009-07-08
NZ576039A (en) 2011-07-29
MA31133B1 (fr) 2010-02-01
RU2009117220A (ru) 2010-11-20
HK1135708A1 (en) 2010-06-11
JP5204779B2 (ja) 2013-06-05
CL2007002889A1 (es) 2008-04-18
KR20090075679A (ko) 2009-07-08
CA2665269A1 (en) 2009-04-02
AU2007304536B2 (en) 2012-08-23
MX2009002962A (es) 2009-04-01
NO20091788L (no) 2009-06-24
AR063140A1 (es) 2008-12-30

Similar Documents

Publication Publication Date Title
BRPI0815920A2 (pt) Composto, composição farmacêutica, e, uso do composto.
BRPI0418251C1 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
BRPI0807487A8 (pt) Uso de antagonistas de il-23 para o tratamento de infecção
SE0301700D0 (sv) Novel compounds
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
EA200901617A1 (ru) Борсодержащие молекулы небольшого размера
ATE534383T1 (de) Zusammensetzungen aus n-ä2,4-bis(1,1- dimethylethyl)-5-hydroxyphenylü-1,4-dihydro-4- oxochinolin-3-carboxamid
UY30759A1 (es) Compuestos quimicos
SE0301653D0 (sv) Novel compounds
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
DE602004021644D1 (de) Gyraseinhibitoren und deren verwendungen
UY30629A1 (es) Nuevo péptido de actinomadura namibiensis
TN2010000074A1 (en) Cyclic depsipeptides
DK1641803T3 (da) Thienopyrimidinderivater som kaliumkanalinhibitorer
TW200734344A (en) Antibacterial agents
CL2009002129A1 (es) Derivados carboxiamida de lantibioticos; proceso de preparacion de dichos lantibioticos; composicion farmaceutica que lo contiene; utiles en el tratamiento de infecciones bacterianas.
CL2008002082A1 (es) Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades.
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
CL2007003519A1 (es) Compuestos derivados de quinolina sustituida; proceso de preparacion; compuesto intermediario; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una infeccion bacteriana.
CL2007001542A1 (es) Compuestos derivados de aminotiazoles, composicion farmaceutica; y uso para el tratamiento de infecciones bacterianas.
UY28313A1 (es) Nonadepsipeptidos acilados
MXPA05008960A (es) Oxazolidinonas de indolona antibacteriales, intermedios para su preparacion y composiciones farmaceuticas que las contienen.
CL2007001910A1 (es) Compuestos derivados de penem; composicion farmaceutica; y uso en el tratamiento de una infeccion bacteriana.
CL2007003517A1 (es) Compuestos derivados de quinolina sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una infeccion bacteriana.
CL2008001719A1 (es) Compuestos derivados de [1,10]-fenantrolina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades neurodegenerativas o hematologicas.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170906